Biomarker and gene detection kit for identifying and diagnosing benign and malignant thyroid nodules
Through biomarkers and gene detection kits for thyroid nodules, combined with tiled probe design, detection of genes such as BRAF, KRAS, HRAS and RET, the thyroid nodule multigene detection kits in the prior art are solved. The high price and missed detection have achieved low-cost and accurate differential diagnosis of benign and malignant thyroid nodules, improving diagnostic efficiency and economic universality.
Patent Information
- Application Number
- CN202411444781.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-03-19
- Filing Date
- 2024-10-16
- Publication Date
- 2024-11-29
AI Technical Summary
The existing thyroid nodule multigene detection kit is expensive, and it can't meet the needs of the industry, and there is a risk of missing detection of unknown mutations, resulting in high detection costs and low efficiency.
Biomarkers for identifying benign and malignant thyroid nodules are used, including BRAF V600E, KRAS Q61K, KRAS Q61R, KRAS G13V, HRAS Q61K, HRAS Q61R, HRAS G13R and other gene mutation detection sites, RET-CCDC6, RET-NCOA4, NTRK3 - Gene fusion detection sites such as ETV6, combined with the design of stacked probes, cover hot gene areas, and provide nucleic acid extraction, library construction, hybridization capture and sequencing kits to reduce detection costs and improve diagnostic efficiency.
It realizes low-cost and accurate differential diagnosis of benign and malignant thyroid nodules, avoids missed detection, improves the final diagnosis rate, reduces the sequencing range and cost, and improves the economic universality and efficiency of detection.
Smart Images

Figure CN119040465A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of molecular biology, and in particular to a biomarker and a gene detection kit for differential diagnosis of benign and malignant thyroid nodules. Background Art
[0002] The current diagnosis of thyroid nodules is mainly based on "thyroid color Doppler ultrasound combined with color Doppler ultrasound-guided fine needle aspiration biopsy (FNAC)". For thyroid nodules that cannot be clearly diagnosed by the above examinations (uncertain thyroid nodules), multi-gene detection tools are considered to further clarify the diagnosis (based on the ATA thyroid nodule diagnosis guidelines). The current multi-gene detection tools are mainly "RNA-GEC" and "DNAv3" developed abroad based on the NGS platform. This detection tool can achieve a sensitivity of 93%, a specificity of 81%, a positive predictive value of 68%, a negative predictive value of 97%, and an accuracy rate of 85% for the diagnosis of thyroid nodules.
[0003] The above detection methods are mainly used for the diagnosis of uncertain thyroid nodules. The main principle is based on the difference in DNA and RNA between thyroid cancer tissue and normal thyroid tissue. The basic NGS technology is used to detect thyroid cancer-related genes in FNA samples. Fresh FNA samples are stored in preservation fluid, and Micro-RNA and DNA co-extraction technology is used to extract RNA and DNA from the tissue. The extracted RNA and DNA are qualitatively analyzed, and the sequencing library is constructed. TM The S5 sequencer performs detection, data analysis, and comprehensive data quality control analysis to obtain the mutation information of the sample (DNA mutation and RNA fusion), screen for specific mutations, and then determine the benign or malignant nature of the nodule based on the gene mutation.
[0004] Patent application number CN 202210502980.X discloses a biomarker, a multi-gene joint detection kit and an application for distinguishing benign and malignant thyroid nodules. The biomarker group includes at least one of 8 DNA single base mutations and 4 gene fusions; the 8 DNA single base mutations are selected from BRAF gene V600E, TERT gene C228T / C250T, KRAS gene G12C / G12V / Q61R, NRAS gene Q61R, HRAS gene Q61R, and the 4 gene fusions are selected from CCDC6-RET (Exon1-Exon12), NCOA4-RET (Exon8-Exon12), PAX8-PPARG (Exon10-Exon2), and ETV6-NTRK3 (Exon4-Exon14). Patent application number CN 202111162079.4 discloses a test kit for auxiliary diagnosis and medication guidance of thyroid cancer, which consists of a combination of exon region and TERT promoter region detection; the exon region is BRAF, DICER1, HRAS, IDH2, KRAS, NRAS, PIK3CA, RET, TP53 exon region; the test kit can detect 10 genes. Patent application number CN 201910592171.0 discloses a primer and a kit for detecting gene mutations related to benign and malignant thyroid nodules, which can simultaneously detect mutations at 15 sites of 6 genes and 3 fusion gene mutations, including BRAF gene, KRAS gene, HRAS gene, NRAS gene, TERT gene, EIF1AX gene and RET / PTC1 fusion, RET / PTC3 fusion, PAX8 / PPARγ fusion. Patent application number CN 201811634541.4 discloses a kit for detecting thyroid cancer pathogenicity-related gene mutations based on high-throughput sequencing technology. It includes the detection of 18 mutation sites of 6 genes, BRAF, NRAS, KRAS, HRAS, TERT, and TP53, and 3 fusion genes, CCDC6 / RET, NCOA4 / RET, and PAX8 / PPARg. Patent application number CN 201680082789.7 discloses a composition for screening mutations in thyroid cancer, and multiple thyroid cancer-related genes include BRAF, NRAS, HRAS, KRAS, PIK3CA, TP53, CTNNB1, PTEN, TSHR, AKT1, GNAS, RET, EIF1AX, and TERT promoter. These detection kits detect too many genes with no diagnostic value and are expensive. The above schemes can only perform amplification detection on known hot spots, and there is a risk of missing unknown mutations. Or they are large-panel detection schemes based on NGS detection. Because the detection area is too large, the gene combination for screening the benign and malignant nature of the thyroid gland is not available.This results in waste of sequencing data, higher testing costs and low efficiency.
[0005] In summary, the existing thyroid nodule multi-gene detection kits can only differentiate between benign and malignant thyroid nodules of uncertainty, are expensive and lack economic universality, detect too many genes with no diagnostic value, and cannot meet current industry needs. Summary of the invention
[0006] In response to the above problems, the present invention provides a biomarker and gene detection kit for differential diagnosis of benign and malignant thyroid nodules with low detection cost, more gene focus, and compatibility with unknown mutations. It achieves a more focused detection of genes, compatibility with unknown mutations, and reduces the detection cost while streamlining the target genes to be detected, making the data more precise, and the analysis process more simplified and efficient, laying the foundation for the popularization of this test.
[0007] The inventors found in their work that five genes, "BRAF V600E", "RET", "HRAS", "KRAS", and "NTRK3", can already determine whether thyroid nodules are benign or malignant.
[0008] In view of this, the technical solution adopted by the present invention is: a biomarker for differential diagnosis of benign and malignant thyroid nodules, including at least one gene mutation detection site: BRAF V600E, KRAS Q61K, KRAS Q61R, KRAS G13V, HRASQ61K, HRAS Q61R, HRAS G13R; or / and at least one gene fusion detection site: RET-CCDC6, RET-NCOA4, NTRK3-ETV6.
[0009] The present invention also includes the use of biomarkers in preparing products for differential diagnosis of benign and malignant thyroid nodules.
[0010] The present invention also provides the use of biomarkers in preparing capture probes for distinguishing benign and malignant thyroid nodules.
[0011] Furthermore, the capture probe adopts a shingled probe design, and the coverage of the gene region in the biomarker by the probe reaches 100%, covering the CDS region and intron region in the gene.
[0012] Furthermore, the probe covers the exon region and the junction of exons and introns of all candidate genes; the junction of exons and introns refers to at least 10-100 bp upstream and downstream of the exon.
[0013] The present invention again provides a gene detection kit for differential diagnosis of benign and malignant thyroid nodules, comprising the capture probe.
[0014] Furthermore, it also includes a nucleic acid extraction kit, a library construction kit, a hybridization capture kit, and a sequencing kit.
[0015] Furthermore, the nucleic acid extraction kit includes DNA shearing enzyme, end-repair enzyme, DNA ligase, polymerase, and buffer; the library construction kit includes Index primers; the hybridization capture kit includes Human Cot-1 DNA, closed adapter sequence, and capture probe; the sequencing kit includes purification magnetic beads and streptavidin magnetic beads. The details are shown in the following table:
[0016]
[0017] Finally, the present invention provides the application of the gene detection kit in constructing a benign and malignant thyroid nodule differential diagnosis system. The benign and malignant thyroid nodule differential diagnosis system comprises a sequencer.
[0018] The number of thyroid cancer cases in China reaches more than 200,000 per year, and the incidence rate is increasing year by year. At present, the differentiation of benign and malignant thyroid tumors mainly adopts FNA cytology detection. However, this method varies due to the experience and ability of diagnostic institutions and cytopathologists. In actual applications, 15%-40% of "follicular tumors" or "suspicious follicular tumors" are actually malignant. The present invention adopts a multi-gene detection method to ensure full coverage of hotspot genes, and effectively improves the final diagnosis rate while strictly controlling the sequencing range and cost. The kit of the present invention covers the hotspot detection genes and also detects KRAS Q61K and HRAS Q61K, avoiding missed detection. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 It is a detection flow chart of the present invention. DETAILED DESCRIPTION
[0020] Embodiment 1:
[0021] This embodiment provides a method for detecting benign or malignant thyroid nodules based on high-throughput sequencing, wherein the detection method includes specifically detecting gene variation based on high-throughput sequencing;
[0022] The gene variation includes gene mutation and gene fusion. The detection genes of gene mutation include BRAF gene, HRAS gene and KRAS gene; the detection genes of gene fusion include RET gene and NTRK3 gene.
[0023] In an embodiment, if Figure 1 As shown, a method for detecting benign or malignant thyroid nodules based on high-throughput sequencing method at least comprises the following steps:
[0024] Step 1: Sample preparation: DNA is extracted from the patient's thyroid FNA sample;
[0025] Step 2: Library construction and probe capture: The extracted DNA is broken, and the breaking methods include but are not limited to: enzyme digestion and mechanical shearing. Then, adapters are added to both ends of the DNA fragments for library construction, and customized probes are used to capture the target gene;
[0026] Step 3: Sequencing: Use NGS platform to perform deep sequencing on the library. NGS platform includes but is not limited to: Illumina platform and BGI platform;
[0027] Step 4: Bioinformatics analysis: Compare the DNA sequencing results with the human reference genome to determine the gene mutation and fusion status of the tested sites of the sample gene.
[0028] Embodiment 2:
[0029] Another embodiment of the present invention provides a kit for detecting benign and malignant thyroid nodules, the kit comprising a reagent for specifically detecting gene mutations.
[0030] The gene variation includes gene mutation and gene fusion. The detection genes of the gene mutation include BRAF gene, KRAS gene, and HRAS gene. The BRAF gene mutation detection sites include: V600E; the KRAS gene mutation detection sites include: Q61K, Q61R, and G13V; the HRAS gene mutation detection sites include: Q61K, Q61R, and G13R.
[0031] The gene fusion detection genes include RET gene and NTRK3 gene; the RET gene fusion detection sites include: RET-CCDC6, RET-NCOA4; the NTRK3 gene fusion detection sites include: NTRK3-ETV6.
[0032] Mutations in the proto-oncogene BRAF drive the proliferation, growth, and differentiation of tumor cells. Currently, more than 30 BRAF mutations have been detected, of which V600E accounts for more than 80%. BRAF V600E mutations can lead to persistent activation of the RAF / mitogen-activated protein kinase (MAPK) signaling pathway, causing changes in tumor cell differentiation, proliferation, metabolism, and growth. The detection rate of BRAF V600E mutations in Chinese PTC patients is 79%, much higher than that in the United States (TCGA data 59.7%).
[0033] The HRAS gene is an important member of the RAS gene family, encoding a small GTP-binding protein that plays an important role in cell signaling. HRAS protein is mainly involved in regulating cell proliferation, differentiation and survival. Under normal circumstances, HRAS helps cells make appropriate growth and differentiation decisions by responding to external signals. However, mutations in the HRAS gene may lead to the continuous activation of the protein it encodes, causing uncontrolled cell proliferation. This continuous activation plays a key role in the development of many types of tumors, including thyroid cancer.
[0034] The KRAS gene also belongs to the RAS gene family and also encodes a small GTP-binding protein that is critical in the cell signaling process. The KRAS protein plays a role in the regulation of cell growth, differentiation, and apoptosis. KRAS mutations are particularly associated with some subtypes of thyroid cancer, especially those that are insensitive to conventional treatments such as radioactive iodine therapy. In addition, KRAS mutations may play a key role in the progression and prognosis of thyroid cancer, especially in relation to the aggressiveness and potential metastasis of the tumor.
[0035] The RET gene is also a proto-oncogene. The protein it encodes is a tyrosine kinase (glial cell neurotrophic factor family) receptor that can be activated by autophosphorylation of intracellular tyrosine residues, triggering signal pathways such as RAS-MARK and PI3K-AKT that are related to cell proliferation and survival. RET in situ gene fusion mainly recombines by breaking itself and joining with other genes to form a new fusion gene. The RET fusion gene causes the tyrosine activation domain to change conformation, exposing phosphorylation sites to activate RET, enhancing signal transduction function, and leading to tumorigenesis. Studies have confirmed that in PTC, CCDC6 and NCOA4 are the most common fusion partners, accounting for about 90% of RET / PTC gene fusions.
[0036] The incidence of NTRK3 gene fusion in papillary thyroid cancer is about 2%-3%, second only to RET gene fusion. The most common fusion type is the fusion of ETV6 gene and NTRK3 gene. This fusion also leads to the expression of chimeric oncoprotein, which in turn activates the MAPK signaling pathway and leads to tumorigenesis.
[0037] Example 3: Biomarkers and gene detection kit detection method for differential diagnosis of benign and malignant thyroid nodules.
[0038] The biomarkers for differential diagnosis of benign and malignant thyroid nodules include gene mutation detection sites: BRAF gene mutation detection sites include: V600E; KRAS gene mutation detection sites include: Q61K, Q61R, G13V; HRAS gene mutation detection sites include: Q61K, Q61R, G13R.
[0039] Gene fusion detection sites: RET gene fusion detection sites include: RET-CCDC6, RET-NCOA4; NTRK3 gene fusion detection sites include: NTRK3-ETV6.
[0040] The detection method of this embodiment comprises the following steps:
[0041] 1 Prelibrary Construction
[0042] Take 50 ng each of the negative control (NC) and positive control (PC) in the kit and test them simultaneously with the samples to be tested.
[0043] 1.1 Enzymatic fragmentation
[0044] 1.1.1 Take 0.2mL PCR tubes according to the number of samples to be tested and mark the sample number on the tube cap.
[0045] 1.1.2 Prepare each fragmentation reaction on ice by adding the components in the following order:
[0046] Components Volume (μL) DNA sample (50-100ng) 35 Reagent 1 5 Reagent 2 10 Total volume 50
[0047] NOTE: KAPA Fragmentation Buffer and enzyme can be premixed and kept on ice prior to reaction setup and dispensed as a single solution. Note that the volume of buffer is less than the volume of enzyme in this reaction.
[0048] 1.1.3 Gently vortex and briefly centrifuge to settle. Place the PCR plate / tubes back on ice and proceed to the next step immediately.
[0049] 1.1.4 Incubate in a PCR instrument, precool to 4°C, and program as follows.
[0050] A heated lid is not required for this step. If a heated lid is used, set its temperature to ≤50°C.
[0051]
[0052] 1.1.5 After the reaction is completed, take it out of the PCR instrument and place it on an ice box before proceeding to the next step of reaction.
[0053] 1.2 End repair, add "A" to the 3' end
[0054] 1.2.1 Reaction system preparation
[0055] Prepare the reaction system for each reaction on an ice box according to the following table:
[0056]
[0057]
[0058] Note: It is best to premix the buffer and enzyme mix and add them in a single pipetting step. The premix can be kept at room temperature for ≤24 hours.
[0059] 1.2.2 Gently vortex and briefly centrifuge to settle. Place the reaction plate / tubes back on ice and proceed to the next step immediately.
[0060] 1.2.3 Run the program
[0061] Place the PCR tube in the PCR instrument, set the temperature of the PCR instrument's hot cover to 85°C, and select the program. The PCR reaction program is as follows:
[0062] Reaction temperature time 65℃ 30min 4℃ Insulation
[0063] Cover the hot cover, run the PCR program, and proceed to the next experiment immediately after the program ends.
[0064] 1.3 Connector connection
[0065] 1.3.1 Reaction system preparation
[0066] Configure the reaction system according to the table below:
[0067] Reaction system components (fragmented DNA) Volume (μL) Reagent 8 5 Reagent 5 30 Reagent 6 10 End repair and A-tailing reaction products (1.2.3 products) 60 <![CDATA[ddH2O]]> 5 Total volume 110
[0068] Note: This operation is performed on an ice box. If a large amount of sample is operated at one time, the reaction solution needs to be pre-mixed, but reagent 8 (universal connector) should not be pre-mixed. The best operation method is to first mix reagent 8 and the sample after the reaction in step 1.2.3, and then add the pre-mixed reaction solution, which can effectively reduce the probability of connector self-ligation.
[0069] 1.3.2 Add the PCR reaction product from 1.2.3 to the reaction tube configured according to 1.3.1, shake for a few seconds to mix, and centrifuge briefly to ensure that the liquid is at the bottom of the tube.
[0070] 1.3.3 Run the program
[0071] Turn on the PCR instrument, set the heat cover to "no heat cover", put the sample tube into the PCR instrument, and run the program. The PCR reaction program is as follows:
[0072] Reaction temperature time 20℃ 15min 4℃ Insulation
[0073] 1.4 Post-ligation purification
[0074] 1) 30 minutes in advance, bring reagent 19 (magnetic microspheres) to room temperature, equilibrate the magnetic beads and set aside;
[0075] 2) Take out a new 0.2mL eight-tube strip, mark the sample number on the tube wall, and dispense the magnetic beads (88μL / tube) in an amount equal to 0.8 times the volume of the reaction product in 1.3.3 for later use;
[0076] 3) Add all the reaction products (110 μL) of step 1.3.3 into the corresponding eight-tube strips containing magnetic beads, and mix by gently pipetting for 6 times;
[0077] 4) Incubate at room temperature for 5 minutes, and place the sample tube on a magnetic rack for 2 minutes to clarify the solution;
[0078] 5) Remove the supernatant (be careful not to absorb the magnetic beads), keep the sample tube on the magnetic rack, then add 200 μL of 80% ethanol solution prepared on the day into the tube, rotate the eight-tube strip 180° and place it on the magnetic rack, let it stand for 30 seconds; rotate it 180° again and let it stand for 30 seconds.
[0079] 6) Remove the supernatant, add 200 μL of 80% ethanol solution prepared on the same day to the centrifuge tube, keep the centrifuge tube on the magnetic rack, rotate the eight-tube strip 180° and place it on the magnetic rack, let it stand for 30 seconds; rotate it 180° again and let it stand for 30 seconds before completely removing the supernatant (it is recommended to use a 10 μL pipette to remove the residual ethanol solution at the bottom, and pay attention to replacing the pipette tip in time);
[0080] 7) Let stand at room temperature for 5 minutes to allow the residual ethanol to evaporate completely;
[0081] 8) Add 25 μL of ddH2O, remove the eight-tube strip from the magnetic rack, gently pipette to resuspend the magnetic beads to avoid bubbles, and let stand at room temperature for 5 minutes;
[0082] 9) Place the sample tube on the magnetic rack for 2 minutes. After the solution is clarified, use a pipette (remember to replace the pipette tip in time) to aspirate 20 μL of supernatant and transfer it to a new eight-tube strip. Mark the sample number on the tube wall and prepare for the next reaction.
[0083] 1.5 PCR amplification
[0084] 1.5.1 Prepare the reaction system:
[0085] 1) Configure the reaction system according to the table below:
[0086] Reaction system components (fragmented DNA introduced into double-ended UDI) Volume (μL) Sample from step 1.4.9 20 Reagent 7 25 Reagent 9 5 Total volume 50
[0087] 2) Use a pipette (remember to replace the pipette tip in time) to gently pipette to mix, then centrifuge briefly to allow the liquid to settle at the bottom of the tube.
[0088] Note: Select a different Index (reagent 9, A1-H2) for each sample and record the Index number (well number) of each sample.
[0089] 1.5.2 PCR amplification procedure
[0090] Place the reaction tube on a PCR instrument, set the program to a hot cover temperature of 105°C, the reaction temperature and cycle number are as shown below, and start the PCR program.
[0091]
[0092] 1.6 Purification after PCR amplification
[0093] 1) Take out a new 0.2mL eight-tube strip according to the number of samples, mark the sample number with a marker pen, and dispense 50μL of reagent 19 (magnetic microspheres) into the tube. Add the sample from step 1.5.2 to the eight-tube strip and mix well with a pipette to avoid bubbles.
[0094] 2) Incubate at room temperature for 5 minutes and place the sample tube on the magnetic rack for 2 minutes;
[0095] 3) Remove the supernatant (be careful not to absorb the magnetic beads), keep the sample tube on the magnetic rack, then add 200 μL of 80% ethanol solution prepared that day into the tube, rotate the eight-tube strip 180° and place it on the magnetic rack, let it stand for 30 seconds; rotate it 180° again and let it stand for 30 seconds.
[0096] 4) Remove the supernatant (be careful not to absorb the magnetic beads), keep the sample tube on the magnetic rack, then add 200μL of the 80% ethanol solution prepared on the day into the tube, rotate the eight-tube strip 180° and place it on the magnetic rack, let it stand for 30 seconds; rotate it 180° again and let it stand for 30 seconds before completely removing the supernatant (it is recommended to use a 10μL pipette to remove the residual ethanol solution at the bottom, and pay attention to replacing the tip in time);
[0097] 5) Let stand at room temperature for 5 min to allow the residual ethanol to evaporate completely;
[0098] 6) Add 30 μL ddH2O, remove the sample tube from the magnetic rack, gently pipette to resuspend the magnetic beads to avoid bubbles, let stand at room temperature for 2 minutes to clarify the solution, and transfer the supernatant to a 0.2 mL PCR tube marked with the corresponding sample number.
[0099] 7) Take 1 μL of sample using a pipette (remember to replace the pipette tip in time), measure the library concentration using Qubit, and record the library concentration.
[0100] 8) The library concentration must be ≥25ng / μL, and the total amount of the pre-library must be ≥750ng.
[0101] 1.7 Pre-library storage: The constructed pre-library is stored in the -20℃ library storage area or used for the next experiment.
[0102] 2. Hybridization Capture
[0103] 2.1 Preparation before the experiment
[0104] 10 minutes before the experiment, take out reagents 10, 11, and 12 in reagent kit 3 and place them on ice. After they are dissolved, mix them well and set aside. When the probe is used for the first time, it needs to be packaged in 0.2mL PCR tubes as needed (use a pipette to dispense liquids, and pay attention to replacing the gun tip in time to avoid cross contamination of reagents), and store in a -80℃ refrigerator. Take a tube to thaw on ice before use, and immediately freeze it in a 20℃ refrigerator after use. Each tube of probe should not be frozen and thawed more than 3 times. If it is not used up after the third freeze-thaw, it should be discarded and cannot be used.
[0105] 2.2 Library hybridization
[0106] 1) Preparation of reaction system: Take a 0.2 mL PCR tube, label it according to the sample number, and prepare the sample library and the corresponding blocks according to the reaction system in the table below:
[0107] Reaction system components Volume (μL) From the Pre-Library Total amount is no more than 6μg (single pre-library 500ng) Reagent 10 7
[0108] Note: To ensure that each library in the mixed sample receives equal sequencing reads, it is important to ensure equal mixing in this step. Accurate quantification and pipetting operations are extremely critical.
[0109] 2) Vacuum concentration: Place the prepared sample into a vacuum frozen concentration centrifuge (turn on the frozen concentration centrifuge first to lower the temperature to below -20°C), open the PCR tube cover, start the centrifuge, turn on the vacuum pump, and begin concentration (pay attention to the concentration time to avoid excessive drying of the sample and sample loss). When the sample is concentrated to 10 μL or slightly less than 10 μL, add ddH2O to make up to 10 μL if it is less than 10 μL, gently blow to mix, centrifuge briefly, and place on ice for later use.
[0110] 3) Take 5 μL of reagent 11 and 2 μL of probe and place them in a new 0.2 mL PCR tube. Mix by gently pipetting. Centrifuge briefly and place on ice for later use.
[0111] 4) Use a pipette (remember to replace the pipette tip in time) to draw up 13 μL of reagent 12 and mix with the concentrated library. Add all the mixed samples to the reagent prepared in step (3), shake and mix, centrifuge briefly, and place on a 96-well plate. It does not need to be placed on an ice box.
[0112] 5) Set the PCR program as follows: (adjust the temperature of the heated cover to 85°C)
[0113] Reaction temperature time 80℃ 5min 50℃ Hold
[0114] Note: Place the PCR tube on the PCR instrument, cover with a hot lid, run the above program, and hybridize overnight (the hybridization time must be greater than 8 hours);
[0115] 2.3 Post-capture reaction
[0116] 2.3.1 Preparation of capture magnetic beads
[0117] 1) 30 min in advance, remove reagent 18 from 4°C and resuspend by vortexing;
[0118] 2) Take 50 μL of reagent 18 and place it in a new 1.5 mL centrifuge tube. Place it on a magnetic rack and let it stand for 1 min or until the solution is clear.
[0119] Remove the supernatant;
[0120] 3) Remove the centrifuge tube from the magnetic stand, add 200 μL of reagent 13 and shake for a few seconds to resuspend the magnetic beads;
[0121] 4) Place on the magnetic stand for 1 min or when the solution is clear, remove the supernatant;
[0122] 5) Repeat steps (3)-(4) twice, washing the magnetic beads three times in total;
[0123] 6) Remove the centrifuge tube from the magnetic rack, add 180 μL of reagent 13, shake and mix for a few seconds, resuspend the magnetic beads and wait for
[0124] At the end of this step, there is no need to put the centrifuge tube back into the magnetic stand for magnetic absorption.
[0125] 2.3.2 Capture of target region DNA library
[0126] 1) Remove the hybridization product from the PCR instrument (if one person operates too many samples and the transfer is slow, it is recommended to remove them from the PCR instrument in batches, and the remaining hybridization products are still placed in the PCR for incubation at 50°C. According to the sample number on the 0.2mL PCR, write the corresponding number on the cap of the 1.5mL centrifuge tube after resuspending in step 2.3, and then transfer the hybridization product to the tube, pay attention to check the number, use a pipette to mix 6 times, and place it on a rotating mixer at room temperature for 30 minutes. The speed of the mixer should not be too high, and it is recommended not to exceed 10 rpm;
[0127] 2) Remove the sample tube from the rotary mixer, centrifuge it briefly, and place it on a magnetic rack at room temperature for 1 min or remove the supernatant when the solution is clear;
[0128] 3) Add 200 μL of reagent 15 to the sample tube, shake and mix for a few seconds, and place it on a rotary mixer for 15 minutes. The speed of the mixer should not be too high, and it is recommended not to exceed 10 rpm;
[0129] 4) Remove the sample tube from the rotary mixer, centrifuge it briefly, and place it on a magnetic rack at room temperature for 1 min or remove the supernatant when the solution is clear;
[0130] 5) Add 200 μL of 50°C preheated reagent 14 to the sample tube, shake and mix for a few seconds, and incubate at 50°C in a constant temperature metal bath for 10 minutes; (the reagents and instruments used in this step must be preheated 10 minutes in advance to ensure the orderly progress of the experiment)
[0131] 6) Take the sample tube out of the metal bath, centrifuge briefly (so that the water vapor at the top of the sample tube will be retained at the bottom and will not affect the next step of the experiment), place the centrifuge tube on the magnetic rack for 1 minute or when the solution is clear, remove the supernatant;
[0132] 7) Repeat steps (5)-(6) twice, for a total of 3 times;
[0133] 8) Add 200 μL of 80% ethanol prepared fresh on the same day to the sample tube, rotate the tube for one week to allow the ethanol to fully contact the magnetic bead product, let it stand for 30 seconds and then completely remove the ethanol solution (you can use a 10 μL pipette to remove the residue, and be sure to replace the pipette tip in time), dry it at room temperature, and make sure that the ethanol is completely evaporated;
[0134] 9) Add 24 μL Nuclease free water to the PCR tube, remove the centrifuge tube from the magnetic stand, and gently blow 6 times to resuspend the magnetic beads for later use. At the end of this step, there is no need to put the centrifuge tube back into the magnetic stand for magnetic absorption.
[0135] 2.3.3 Post-PCR
[0136] 1) Prepare the reaction system according to the number of samples to be tested. The reaction system for a single sample is as follows:
[0137] Reaction system components A reaction standard Reagent 7 25μL Reagent 16 1μL Nuclease-free water 12μL Sample with magnetic beads from step 2.3.2 12μL Total volume 50μL
[0138] Note: This operation is performed on an ice box.
[0139] 2) Mix the reaction system, centrifuge briefly, place on ice, and proceed to the next step of the experiment immediately;
[0140] 3) Place the PCR reaction tube / plate into the PCR instrument. Set the program to a hot cover temperature of 105°C, the reaction temperature and the number of cycles as shown below, and start the PCR program.
[0141]
[0142] 2.3.4 Library enrichment and purification
[0143] 1) Equilibrate reagent 19 at room temperature for at least 30 min; vortex for 10 s to mix thoroughly;
[0144] 2) Place the PCR amplification product from 2.3.3 on a magnetic rack and transfer the supernatant to a new tube;
[0145] 3) Add 70 μL of reagent 19 to a new tube containing 50 μL of PCR amplification product;
[0146] 4) Vortex thoroughly to mix and incubate at room temperature for 5 minutes;
[0147] 5) Place the reaction tube on the magnetic rack;
[0148] 6) After the liquid is clear, carefully discard the supernatant;
[0149] 7) Leave the reaction tube on the magnetic rack and add 200 μL of 80% ethanol prepared on the same day;
[0150] 8) Leave at room temperature for more than 30 seconds;
[0151] 9) Carefully discard the liquid;
[0152] 10) Repeat steps 7-9 above, and then remove all residual ethanol without touching the magnetic beads;
[0153] 11) Leave the tube cap open at room temperature for 5 minutes or until the beads are air-dried (Note: Over-drying the beads may result in reduced yield);
[0154] 12) Remove the reaction tube from the magnetic rack and elute the DNA with 22 μL of 10 mM Tris-HCL, pH 8.0 or PCR grade water;
[0155] 13) Vortex to ensure mixing;
[0156] 14) Incubate at room temperature for 5 min;
[0157] 15) Place the reaction tube back into the magnetic rack to clarify the solution;
[0158] 16) At this point, the supernatant contains the amplified sample library. Take 20 μL of the supernatant and transfer it to a new centrifuge tube and label it according to the sample number.
[0159] 2.4 Library quality control
[0160] Qubit quantification: Take 1μL library and use Qubit to detect library concentration. Library quality inspection standard: concentration greater than 0.5ng / μL, total amount not less than 20ng. Qsep detects library length, the main peak is between 280-400bp;
[0161] 2.5 Library storage: If the library is to be used for subsequent library mixing, it should be temporarily stored in a 4°C refrigerator. If the subsequent steps are not to be performed immediately, it should be stored in a -80°C library storage area for 2 months.
[0162] 3 Sequencing
[0163] It is recommended to use the MGIEasy Universal Library Conversion Kit produced by BGI, circularize the library according to the recommended method, and then use the MGISEQ-2000RS High-throughput Sequencing Reagent Set (App-A) (PE150) to perform sequencing reactions on the MGISeq-2000 sequencer, strictly following the instructions.
[0164] 4. Result Analysis and Reporting
[0165] The data is copied or automatically transferred to the data analysis and reporting integrated machine "Top Analyze" installed with analysis software by Dingjing, and the raw data is analyzed by the capture method data analysis software module. The analysis software can realize the automated analysis from the raw data of the gene sequencer to the report.
[0166] 4.1 The analysis system performs quality control, data cleaning, reference genome alignment, somatic mutation analysis, germline mutation analysis, copy number analysis, mutation function annotation, and sample matching analysis on the sequencing data. The reference genome version used in the analysis process is hg19, and the analysis software includes Fast QC, Trimmomatic, BWA-MEM, GATK, ANNOVAR, data review system, automated reporting system, etc.
[0167] 4.2 Use the breast cancer gene detection site screening system to filter false positive analysis results.
[0168] 4.3 Samples that simultaneously meet Q20 ≥ 90, Q30 ≥ 80, percentage of reads aligned to the reference genome ≥ 90, percentage of target region coverage ≥ 90, average sequencing depth (de-redundancy) of the target region ≥ 100×, and percentage of sequencing depth of the target region ≥ 10× ≥ 90 are qualified samples for analytical quality control.
[0169] 4.4 For samples that have passed the analytical quality control, the data review system is used to confirm the data comparison around the mutation site using IGV, further delete false positive sites, and classify the mutations according to the pathogenicity of the "ACMG Genetic Variation Classification Standards and Guidelines".
[0170] Example 4: Accuracy of biomarkers and genetic testing kits for differential diagnosis of benign and malignant thyroid nodules.
[0171] By testing the positive and negative corporate reference materials that come with this product, we followed the instructions and invested 200 ng to build the library. We then completed the hybridization capture on the machine and analyzed the data off the machine to obtain the mutation frequency. A total of 9 positive reference materials and 3 negative reference materials were tested, and the detection frequencies all fell within the theoretical mutation frequency range. No mutations were detected in the negative reference materials, which was in line with the expected results.
[0172]
[0173] Example 5: Repeatability of biomarkers and genetic testing reagents for differential diagnosis of benign and malignant thyroid nodules.
[0174] By testing the reproducible corporate reference materials that come with this product, we followed the instructions and invested 200 ng to build the library. We then completed the hybridization capture on the machine and analyzed the data off the machine to obtain the mutation frequency. A total of three reproducible reference materials were tested, and each reproducible reference material was tested 10 times to calculate the mutation frequency. The detection frequencies all fell within the theoretical mutation frequency range and the CV values were in line with expectations.
[0175]
[0176] Example 6: Biomarkers and detection limits of genetic testing reagents for differential diagnosis of benign and malignant thyroid nodules.
[0177] By testing the detection limit corporate reference material that comes with this product, we followed the instructions and invested 200 ng to build the library. We then completed the hybridization capture on the machine and analyzed the data off the machine to obtain the mutation frequency. A total of 3 detection limit reference materials were tested and the mutation frequency was calculated. The detection frequencies all fell within the theoretical mutation frequency range, which was in line with expectations.
[0178]
[0179] Example 7: Biomarkers for differential diagnosis of benign and malignant thyroid nodules and genes detected by the gene detection kit.
[0180] The kit of the present invention was used to detect thyroid cancer samples and found that: KRAS Q61K was detected once (papillary thyroid cancer); HRAS Q61K was detected twice (thyroid malignant tumor and medullary carcinoma).
[0181]
Claims
1. A biomarker for differential diagnosis of benign and malignant thyroid nodules, characterized by: Includes at least one of the following gene mutation detection sites: BRAF V600E, KRAS Q61K, KRAS Q61R, KRAS G13V, HRAS Q61K, HRAS Q61R, HRAS G13R; Or / and at least one of the following gene fusion detection sites: RET-CCDC6, RET-NCOA4, NTRK3-ETV6.
2. Use of the biomarker according to claim 1 in the preparation of a product for differential diagnosis of benign and malignant thyroid nodules.
3. Use of the biomarker according to claim 1 in preparing capture probes for distinguishing benign and malignant thyroid nodules.
4. The use according to claim 3, characterized in that: The capture probe adopts a shingled probe design, and the coverage of the gene region in the biomarker by the probe reaches 100%, covering the CDS region and intron region in the gene.
5. The use according to claim 3 or 4, characterized in that: The probe covers the exon region and the splicing site of exons and introns of all candidate genes; the splicing site of exons and introns refers to at least 10-100 bp upstream and downstream of the exon.
6. A gene detection kit for differential diagnosis of benign and malignant thyroid nodules, characterized by: The capture probe comprises any one of claims 3 to 5.
7. The gene detection kit according to claim 6, characterized in that: It also includes nucleic acid extraction kits, library construction kits, hybridization capture kits, and sequencing kits.
8. The gene detection kit according to claim 7, characterized in that: The nucleic acid extraction kit includes DNA shearing enzyme, end-repair enzyme, DNA ligase, polymerase, and buffer; the library construction kit includes Index primers; the hybridization capture kit includes Human Cot-1 DNA, closed linker sequence, and capture probe; the sequencing kit includes purification magnetic beads and streptavidin magnetic beads.
9. Use of the gene detection kit according to any one of claims 6 to 8 in constructing a system for differential diagnosis of benign and malignant thyroid nodules.
10. The use according to claim 9, characterized in that: The system for differential diagnosis of benign and malignant thyroid nodules includes a sequencer.
